UPFRONT BRIEFING
Beeline took full Phase 2 lupus numbers to the ACR Convergence stage: afimetoran, an oral TLR7/8 pill out of the Bristol Myers Squibb attic, beat placebo by about 30 points on SRI-4 at every dose. BioNTech, meanwhile, spent $205M of its €16.2B pile on Scholar Rock's priority review voucher, which is one way to buy time.
Capricor cut 10% of staff and kept building cleanrooms ten days out from its Nov. 22 deramiocel decision. Closer in: Moderna hosts its Analyst Day today, Summit's ivonescimab PDUFA lands Saturday (14 Nov), and Jefferies London opens Monday.
Finally, Jensen Huang isn’t the only one with China on his mind. We analysed 170 biotech licensing deals from 2026: China-origin assets took 39% of deals, 67% of the $245B headline and 12 of the 19 upfronts of $300M or more. Across all deals, only $17.5B (about 7%) was paid upfront. Read the breakdown →
TAPE ACTION

Healthcare sat out the rally: XLV finished flat (0.0%) against a 1.3% S&P 500 gain, while biotech held modestly positive (XBI +0.8%, BBC +0.7%, NBI +0.4%). Single names did the work: Capricor closed +26.5% ten days before its deramiocel decision, and PepGen added another 14.1% after Tuesday's DM1 data.
CoreWeave's beat-and-raise (Q3 revenue $3.66B; 2026 guide $13.0–13.3B) put the AI trade back on: CRWV +24.7%, Nvidia +2.9%, Nasdaq 100 +2.3%, S&P 500 +1.3%, Russell 2000 +0.9%, Dow +0.5%. Bond markets were shut for Veterans Day (10Y last 4.98%), a December hike stays fully priced after Goolsbee called October CPI "borderline disturbing", and Brent rose 1.4% to $92.76 on Iran's nuclear-material stance. After the bell, Nvidia fell ~8% on a WSJ report that its board is preparing to remove Jensen Huang.
THE BIG 3
1️⃣ — Beeline's oral lupus pill beats placebo by 30 points at every dose
Afimetoran, a once-daily oral TLR7/8 inhibitor Beeline licensed from Bristol Myers Squibb in July 2025, posted full Phase 2 results in active moderate-to-severe SLE (n=248, 48 weeks) as an ACR Convergence late-breaker on Wednesday: SRI-4 response was 67.8% (2.5 mg), 64.1% (10 mg) and 66.1% (30 mg) vs 34.4% on placebo (p<0.001 each); BICLA 38.7–50.8% vs 27.9%; 71.9–75.0% tapered steroids to ≤7.5 mg/day vs 50.0%. Phase 3 starts in 2027.
Why it matters: A flat dose response from 2.5 mg to 30 mg with a 30-point SRI-4 gap is rare in lupus, and the lowest dose working gives Beeline room on safety margin. The safety table runs the right way: drug-related serious adverse events 1.1% versus 6.5% on placebo, and no deaths. BICLA separation is narrower at 11 to 23 points, which matters because AstraZeneca's Saphnelo won approval on BICLA, so Phase 3 endpoint choice in 2027 is the design call to watch. A once-daily pill would compete with infused or injected biologics in Benlysta and Saphnelo and lands ahead of Biogen's litifilimab pivotal readouts. Beeline is private, so Bristol Myers Squibb, the licensor, is the listed read-through.
Source: Endpoints
More: Beeline release
2️⃣ — Capricor cuts 10% and builds supply into its Nov. 22 deramiocel decision
Capricor cut ~10% of staff (231 FTEs at end-2025) and slowed work outside deramiocel, including its exosome platform, alongside Q3 results Tuesday; Q3 operating spend rose to $44.7M from $26.3M on launch prep. Its San Diego plant has passed pre-license inspection with first-floor capacity for ~250 patients a year, rising to 2,000–2,500 once the second floor validates in 1H27. FDA action date is Nov. 22 for the narrowed upper-limb DMD indication.
Why it matters: Manufacturing sank the first filing: the July 2025 CRL cited chemistry, manufacturing and controls, and Capricor now has a pre-license inspection behind it. Efficacy is the open question. The FDA's advisory committee voted 9-3 against the cardiomyopathy claim in July, and the August amendment narrowed the ask to HOPE-3's upper-limb primary, which the panel treated more kindly. CEO Linda Marbán said she would be reluctant to walk away if a simple extra study were required, which frames the CRL case as delay rather than write-off. Kaos Capital, a vocal holder, wanted spend moved beyond deramiocel and got the opposite. Wednesday's 26.5% jump means the stock carries approval odds into the date.
Source: Fierce Biotech
More: BioSpace; BioSpace (manufacturing)
3️⃣ — BioNTech pays Scholar Rock $205M cash for a priority review voucher
BioNTech agreed to buy Scholar Rock's FDA priority review voucher for $205M in cash (announced Tue 10 Nov, subject to HSR), for a future filing from its late-stage oncology pipeline. Scholar Rock, which launched ISEMBYLD (apitegromab) in SMA after a Sep. 11 approval, ended Q3 with $413.6M in cash plus up to $150M of debt capacity; CHMP opinion is expected 1H27.
Why it matters: Paying $205M for faster review says BioNTech has a filing where months carry revenue. Candidates on its Q3 slate: gotistobart, whose updated Phase 3 stage 1 nearly doubled median overall survival in squamous NSCLC; pumitamig with BMS; and trastuzumab pamirtecan, where a BLA is under discussion despite modest DYNASTY-Breast02 PFS and more ILD. BioNTech can afford it, with €16.2B in cash and securities at 30 September. For Scholar Rock the cash equals about half its quarter-end balance, without dilution, in the first months of the ISEMBYLD launch. Every rare-disease model that counts a voucher sale now has a fresh comp. HSR clearance is the stated closing condition.
Source: Fierce Pharma
More: BioNTech 6-K; Scholar Rock Q3
EVERYTHING ELSE THAT BROKE
Flagship merged Valo Health and Montai Therapeutics; the combined company keeps the Valo name under CEO Brian Alexander, leads with Phase 1 oral NRF2 agonist MTAI-1025 in UC plus an oral STAT6 inhibitor, and keeps Valo's cardiometabolic and neurodegeneration partnerships. — Fierce Biotech
enGene will start a BLA for non-viral gene therapy detalimogene by year-end; LEGEND pivotal cohort 1 (BCG-unresponsive NMIBC) showed any-time CR 56% and 12-month landmark CR 24% (from 13%), with serious TRAEs in 2%. — enGene
Lilly's open-label Phase 3b TOGETHER-PsA: Taltz plus Zepbound hit ACR50 in 43.7% at one year vs 15.7% on Taltz alone in PsA with obesity (ACR Convergence). — Lilly
FDA put two Chinese compounding-API suppliers, Chongqing Qiancan Technology and Tianjin Healthcare Medical Technology, on import alert with warning letters after both refused records requests. — BioSpace
HELP chair Bill Cassidy scheduled a committee vote on FDA commissioner nominee Heidi Overton while saying he is still undecided. — STAT
Hims & Hers laid out its plan to revive the business after pivoting from compounded to branded GLP-1s. — Endpoints
Amgen detailed dazodalibep's OASIZ-301 Phase 3 in Sjögren's (n≈621): ESSDAI change at week 48 was −5.6 (1,500 mg q4w) and −5.2 (3,000 mg q12w) vs −3.8 on placebo (p<0.001 / p=0.010), with dryness secondaries also hit; OASIZ-303 completes Q4, while Novartis awaits an FDA decision on rival ianalumab. — Fierce Biotech
DEAL FLOW
Track the Deals Shaping Biotech
Track M&A, licensing agreements, IPOs and venture financings. Explore deal values, key terms and transaction details in our regularly updated BioBucks trackers.
M&A / BD&L
BioNTech / Scholar Rock — FDA priority review voucher, $205M cash, subject to HSR (see The Big 3). — Fierce Pharma
Valo Health / Montai Therapeutics — Flagship portfolio merger, combined company keeps the Valo name; terms undisclosed. — Valo release
VC / PRIVATE FINANCINGS
Neurosterix (Addex spin-out) closed a $105M Series B, investors not named, for Phase 2 of NTX-253, a selective M4 PAM in schizophrenia; Addex did not participate and now holds 8.5%. — Endpoints
VectorY extended its Series A by €74.5M ($83.5M) for vectorized antibody gene therapies in neurodegeneration, led by VTx-002. — Endpoints
Eli Radiopharma (Hangzhou) closed a Series A of nearly RMB 400M, led by Huagai Capital with Bayland Capital co-leading, joined by Boyu Ventures, Delian Capital, InnoPinnacle Fund and Haibang Venture; several programs nearing IND. — PR Newswire
IPO / FOLLOW-ON
No notable IPOs or follow-ons since yesterday's edition.
ACADEMIC CORNER
A Phase 3 interim analysis said ravulizumab cut proteinuria more than placebo in IgA nephropathy. — NEJM
A Nature Medicine paper linked TROP2 membrane ratio to datopotamab deruxtecan outcomes in NSCLC. — Nature Medicine
Nature RDD spotlighted the first factor XIa inhibitor to win FDA approval for stroke prevention. — Nature RDD
Know someone who'd like this?
Forward it along. It takes ten seconds and means a lot to us.
ACR posters, a PRV receipt and a PDUFA on Saturday. Pace yourselves.
— The BioBucks Team
